Rheumatoid Arthritis Treatment Market Size, Share, Trend, Outlook, Future Analysis And Synthesis By 2026 Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the most. Treatments available for rheumatoid arthritis aids to relive symptoms and improve the joint function. A comprehensive treatment for RA usually involves integration of patient education, exercise, medications, and surgery (occasionally). The rheumatoid arthritis treatment market can be analyzed based on the drug type, as follows: Biological drugs: • Monoclonal antibodies Non-Biologicals: • Non-steroidal Anti-inflammatory Drugs (NSAIDs) • Corticosteroids • Analgesics • Disease-modifying anti-rheumatic drugs (DMARDs) - IL-6 inhibitors - TNF inhibitors Download PDF Brochure of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/166 NSAIDs and corticosteroid are also the first-line fast acting therapeutic drugs. Acetylsalicylate, naproxen, ibuprofen, etodolac, and diclofenac are the NSAIDs usually prescribed as first-line drugs for RA. These drugs reduce inflammation, and pain. Corticosteroid medications are given either orally or parenterally to reduce inflammation and restore joint mobility and function. These class of drugs are more potent than NSAIDs and therefore usually preferred a first line therapy by prescribers. The global rheumatoid arthritis treatment industry is expected to be driven considerably in near future by DMARDs that form second line slow-acting therapeutic drugs. Longer therapeutic regimen with these drugs increases cost of therapy and also promote remission of joint destruction and deformity. Methotrexate is the most commonly prescribed second line drug for RA and hence, occupies major share in the respective segment of global rheumatoid arthritis treatment market. Tofacitinib (Xeljanz) is the most potential FDA approved Janus kinase (JAK) inhibitor available in the global market of rheumatoid arthritis treatment. Report includes chapters which deeply display the following deliverable about industry : • Rheumatoid Arthritis Treatment Market Research Objective and Assumption • Rheumatoid Arthritis Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Rheumatoid Arthritis Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Rheumatoid Arthritis Treatment Market, By Regions • Rheumatoid Arthritis Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Rheumatoid Arthritis Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Rheumatoid Arthritis Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Rheumatoid Arthritis Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Key statistics pertaining to the global rheumatoid arthritis treatment market: Over time, there is damage to cartilage and mobility function of the affected joint in rheumatoid arthritis patient. • Affects nearly 1.3 million U.S. population (RheumatoidArthritis.org) • Most common in the age group of 30-60 years • Global prevalence varies in the range of 0.3% to 1% (World Health Organization) • Average annual cost of treatment may go up to US $20,000 (RheumatoidArthritis.org) • According to the Arthritis Foundation, people with RA loose more workdays compared to those affected by any other medical condition • According to a Harvard University study published in the Journal of Global Health (2017), prevalence of rheumatoid arthritis in Southeast Asian countries was 0.4%, 0.42 in western Pacific region, and 0.37% in eastern Mediterranean countries Global Key Players Some of the major players in the global rheumatoid arthritis treatment market are Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc., Grab Best Discount on This Research Report @ https://www.coherentmarketinsights.com/insight/ request-discount/166 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology).
© Copyright 2024 Paperzz
